The preliminary joint proxy statement/prospectus was filed this afternoon. Interesting disclosures included under the headline "Background of the Merger." For instance:
"On December 16, 2013, the Uroplasty board of directors held a special meeting...Following a discussion of the alternatives and the proposed process for further exploration of a potential sale of Uroplasty..., the Uroplasty board of directors authorized management to begin a process to explore the viability of a transaction involving the sale of Uroplasty..."
"On January 20, 2014, Piper Jaffray provided an outline of a bid process to five parties, which stated that bids were to be received by Uroplasty by no later than February 18, 2014..."
"On February 19, 2014, the Uroplasty board of directors held a special meeting...At this meeting, Mr. Kill updated the board of directors on the process to explore the viability of a transaction involving the sale of Uroplasty...Kill noted that indications of interest were due on February 18, 2014 and that no indications of interest were received..."
"On August 1, 2014, Mr. Kill received an executed confidentiality agreement from Company A. Mr. Kill subsequently shared specific non-public information that had been requested by Company A...On September 12, 2014, Mr. Kill was informed by Company A that after conducting due diligence they were not interested in acquiring Uroplasty."
"On October 29, 2014, Mr. Kill executed a confidentiality agreement with Company B...On October 30, 2014, Mr. Kill, Mr. Reynolds and Mr. Hammers met in person at Uroplasty headquarters with Company B. At this meeting, Uroplasty shared confidential non-public information to Company B regarding Uroplasty’ performance, industry and products...On November 6, 2014, Mr. Kill provided specific confidential information to Company B to assist them in building financial models in preparation for a presentation to their board of directors in early December...On December 12, 2014, Uroplasty was informed by a representative from Piper Jaffray that Company B would not be making an offer to acquire Uroplasty."
невероятно!!!
"On December 16, 2013, the Uroplasty board of directors held a special meeting...Following a discussion of the alternatives and the proposed process for further exploration of a potential sale of Uroplasty..., the Uroplasty board of directors authorized management to begin a process to explore the viability of a transaction involving the sale of Uroplasty..."
"On January 20, 2014, Piper Jaffray provided an outline of a bid process to five parties, which stated that bids were to be received by Uroplasty by no later than February 18, 2014..."
"On February 19, 2014, the Uroplasty board of directors held a special meeting...At this meeting, Mr. Kill updated the board of directors on the process to explore the viability of a transaction involving the sale of Uroplasty...Kill noted that indications of interest were due on February 18, 2014 and that no indications of interest were received..."
"On August 1, 2014, Mr. Kill received an executed confidentiality agreement from Company A. Mr. Kill subsequently shared specific non-public information that had been requested by Company A...On September 12, 2014, Mr. Kill was informed by Company A that after conducting due diligence they were not interested in acquiring Uroplasty."
"On October 29, 2014, Mr. Kill executed a confidentiality agreement with Company B...On October 30, 2014, Mr. Kill, Mr. Reynolds and Mr. Hammers met in person at Uroplasty headquarters with Company B. At this meeting, Uroplasty shared confidential non-public information to Company B regarding Uroplasty’ performance, industry and products...On November 6, 2014, Mr. Kill provided specific confidential information to Company B to assist them in building financial models in preparation for a presentation to their board of directors in early December...On December 12, 2014, Uroplasty was informed by a representative from Piper Jaffray that Company B would not be making an offer to acquire Uroplasty."
невероятно!!!